Changes in Hong Kong stocks | Jietai Technology-P (07666) closed more than 14% and obtained strategic alliance results with Deerfield, which will focus on “platform+pipeline” IP global cooperation

The Zhitong Finance App learned that Jitai Technology-P (07666) closed up more than 14%. As of press release, it had risen 14.34% to HK$12.2, with a turnover of HK$144 million.

According to the news, recently, Jietai Technology announced that it has achieved the first important result of a strategic alliance with Deerfield to accelerate the global development of next-generation immunotherapy. Jietai Technology and Boulevard Bio, an American biotechnology company founded with Deerfield's support, officially signed an exclusive global licensing agreement to grant it the right to develop, produce and commercialize the three specific TCE (T Cell Engager, T Cell Connector) MTS-128 projects independently developed on a global scale. Cathay Pacific Haitong previously pointed out that Jietai Technology uses a two-wheel drive business model of “platform cooperation+product cooperation” to form a recycling collaborative ecosystem of “technology iteration - commercial application - real data feedback”.

It is worth mentioning that during the 2026 World Artificial Intelligence Conference (WAIC), when talking about the internationalization strategy of AI pharmaceutical companies, Dr. Lai Caida, co-founder, chairman and CEO of Jietai Technology, shared his views and stated that the internationalization of Chinese biomedicine is undergoing a new paradigm shift from Global to China, China to Global, and from Global to Global. As far as Jietai Technology is concerned, it will continue to focus on global cooperation between platform IP and pipeline IP in the short term. In the future, it will continue to explore various business cooperation models such as License, NewCo, and Co-development to truly achieve global to global and continue to receive global revenue.